Shilpa Medicare gets EIR from USFDA for Finished Dosage Formulation Facility

25 Oct 2019 Evaluate

Shilpa Medicare has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) on October 2019, for the Finished Dosage Formulation Facility (Sterile and Non-sterile Dosage Forms) located at 5-20 to 5-26, Pharmaceutical Formulations SEZ, APIIC, Jadcherla in the state of Telangana.

The company's finished dosage form facility was inspected by US FDA from August 29, 2019 to September 6, 2019. USFDA has concluded the Inspection, with determination that the inspection classification of this facility is ‘voluntary action indicated’ (VAI). This facility is in acceptable state of compliance with regards to current good manufacturing practice (CGMP).

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

318.35 -2.00 (-0.62%)
30-Dec-2025 14:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.70
Dr. Reddys Lab 1267.20
Cipla 1486.15
Zydus Lifesciences 902.00
Lupin 2086.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×